Add to Twitter
 
New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuria
• Findings from a post-hoc analysis of the EMPA-REG OUTCOME® trial in adults with type 2 diabetes and chronic kidney disease without overt proteinuria were presented at the 79th American Diabetes Association Scientific Sessions®